azathioprine has been researched along with Hematologic Diseases in 22 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Hematologic Diseases: Disorders of the blood and blood forming tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Azathioprine, a cytostatic and immunosuppressive drug in use for some 30 years, can give rise to life-threatening neutropenia and thrombocytopenia." | 3.70 | [Bone marrow depression after azathioprine. New discoveries on an old drug]. ( Lindstedt, G; Löwhagen, GB, 2000) |
| "Azathioprine toxicity was examined in 64 consecutively treated patients with various neuromuscular diseases." | 3.67 | Azathioprine toxicity in neuromuscular disease. ( Griggs, RC; Kissel, JT; Levy, RJ; Mendell, JR, 1986) |
| "Azathioprine (AZA) is a thiopurine prodrug commonly used in patients with kidney transplantation." | 2.75 | Association between inosine triphosphate pyrophosphohydrolase deficiency and azathioprine-related adverse drug reactions in the Chinese kidney transplant recipients. ( Li, Q; Wu, XC; Xin, HW; Xiong, H; Xiong, L; Yu, AR, 2010) |
| "Prednisone use was associated with higher mortality [HR = 3." | 1.46 | Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy. ( Boice, J; Colombel, JF; Cornillie, F; D'Haens, G; Ghosh, S; Hommes, DW; Huang, Z; Huyck, S; Lindgren, S; Panes, J; Prantera, C; Reinisch, W, 2017) |
| "Overall, 113/164 (69%) patients with Crohn's disease and 83/136 (61%) patients with ulcerative/unclassified colitis had a clinical response by the end of follow-up (median 19 months), while 85 (52%) patients with Crohn's disease and 74 (54%) patients with ulcerative/unclassified colitis were in clinical remission." | 1.43 | Long-term Safety and Efficacy of Low-dose Azathioprine and Allopurinol Cotherapy in Inflammatory Bowel Disease: A Large Observational Study. ( Abdulrehman, A; Ansari, A; Bull, C; Duley, J; Kerr, P; Pavlidis, P; Stamoulos, P, 2016) |
| " Patients with variations of the TPMT gene may be at risk for myelosuppression after they receive a standard dosage of the drug." | 1.35 | Impact of the heterozygous TPMT*1/*3C genotype on azathioprine-induced myelosuppression in kidney transplant recipients in Thailand. ( Angsuthum, S; Avihingsanon, Y; Makarawate, P; Pongskul, C; Praditpornsilpa, K; Sirivongs, D; Tassaneeyakul, W; Vannaprasaht, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (40.91) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 4 (18.18) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Siramolpiwat, S | 1 |
| Sakonlaya, D | 1 |
| Pavlidis, P | 1 |
| Stamoulos, P | 1 |
| Abdulrehman, A | 1 |
| Kerr, P | 1 |
| Bull, C | 1 |
| Duley, J | 1 |
| Ansari, A | 1 |
| Mock, JR | 1 |
| Kolb, TM | 1 |
| Illei, PB | 1 |
| Yang, SC | 1 |
| Lederman, HM | 1 |
| Merlo, CA | 1 |
| Di Salvo, A | 1 |
| Fabiano, C | 1 |
| Mannara, V | 1 |
| Dimarco, M | 1 |
| Orlando, A | 1 |
| Affronti, M | 1 |
| Macaluso, FS | 1 |
| Cottone, M | 1 |
| D'Haens, G | 1 |
| Reinisch, W | 1 |
| Colombel, JF | 1 |
| Panes, J | 1 |
| Ghosh, S | 1 |
| Prantera, C | 1 |
| Lindgren, S | 1 |
| Hommes, DW | 1 |
| Huang, Z | 1 |
| Boice, J | 1 |
| Huyck, S | 1 |
| Cornillie, F | 1 |
| Xin, HW | 2 |
| Xiong, H | 2 |
| Wu, XC | 2 |
| Li, Q | 2 |
| Xiong, L | 2 |
| Yu, AR | 2 |
| Vannaprasaht, S | 1 |
| Angsuthum, S | 1 |
| Avihingsanon, Y | 1 |
| Sirivongs, D | 1 |
| Pongskul, C | 1 |
| Makarawate, P | 1 |
| Praditpornsilpa, K | 1 |
| Tassaneeyakul, W | 2 |
| Taylor-Gjevre, RM | 1 |
| Gjevre, JA | 1 |
| Nair, BV | 1 |
| Matern, D | 1 |
| Hakemi, M | 1 |
| Shahebrahimi, K | 1 |
| Ganji, MR | 1 |
| Najafi, I | 1 |
| Broumand, B | 1 |
| Black, AJ | 1 |
| McLeod, HL | 1 |
| Capell, HA | 1 |
| Powrie, RH | 1 |
| Matowe, LK | 1 |
| Pritchard, SC | 1 |
| Collie-Duguid, ES | 1 |
| Reid, DM | 1 |
| Löwhagen, GB | 1 |
| Lindstedt, G | 1 |
| Schmidt, P | 1 |
| Kopsa, H | 1 |
| Balcke, P | 1 |
| Zazgornik, J | 1 |
| Pils, P | 1 |
| Barbanel, C | 1 |
| Kreis, H | 1 |
| Crosnier, J | 1 |
| Boyd, IW | 1 |
| Lovisetto, P | 1 |
| Manachino, D | 1 |
| Biarese, V | 1 |
| Marchi, L | 1 |
| Andrione, P | 1 |
| Kissel, JT | 1 |
| Levy, RJ | 1 |
| Mendell, JR | 1 |
| Griggs, RC | 1 |
| Sánchez-Fayos, J | 1 |
| Wolff, SM | 1 |
| Fauci, AS | 1 |
| Horn, RG | 1 |
| Dale, DC | 1 |
| Rosman, M | 1 |
| Bertino, JR | 1 |
| Scheitlin, W | 1 |
| Brunner, F | 1 |
| Gerhartz, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Crohn's Disease European Registry. A Prospective, Observational, Postmarketing Safety Surveillance Registry of Patients Treated With Remicade® or Standard Therapy[NCT00705614] | 2,662 participants (Actual) | Observational | 2003-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of participant fatalities was evaluated throughout the study. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 30 |
| Standard Therapy | 14 |
| Switched to Remicade | 4 |
The number of participants with demyelinating neurological disorders was evaluated. Demyelinating neurological disorders were defined as multiple sclerosis, optic neuritis, peripheral syndromes such as peripheral neuropathy, mononeuropathy multipex, cranial neuropathies, Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, and transverse myelitis. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 4 |
| Standard Therapy | 1 |
| Switched to Remicade | 0 |
The number of participants wtih hematologic conditions was evaluated. A hematologic condition was defined as thrombocytopenia, neutropenia, pancytopenia, granulocytopenia, leukopenia, or aplastic anemia. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 50 |
| Standard Therapy | 11 |
| Switched to Remicade | 7 |
The number of participants with infusion-related reactions and/or hypersensitivity was evaluated. An infuson-related reaction/hypersensitivity was defined as as an acute reaction, including anaphylactic shock that occurs after the onset of the infusion or within the 1- to 2-hour observation period following the end of the infusion. Delayed hypersensitivity reactions (myalgia and/or arthralgia with fever and rash within 14 days of the infusion) were included. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 173 |
| Standard Therapy | 1 |
| Switched to Remicade | 28 |
The number of participants wtih lymphoproliferative disorders and/or malignancies was evaluated. A lymphoproliferative disorder and /or malignancy included, but was not limited to, lymphoma, gastrointestinal cancer, skin cancer (including basocellular and squamous carcinoma, melanoma) and in situ cervical carcinoma. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 49 |
| Standard Therapy | 21 |
| Switched to Remicade | 8 |
The number of participants with new or worsening congestive heart failure was evaluated throughout the study. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 1 |
| Standard Therapy | 1 |
| Switched to Remicade | 0 |
The number of participants experiencing serious infections was evaluated. Serious infections included, but were not limited to, tuberculosis, opportunistic infections (such as Pneumocystis carinii [PCP] pneumonia, listeriosis, atypical mycobacteria, and histoplasmosis), salmonellosis,and serious viral infections. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 132 |
| Standard Therapy | 47 |
| Switched to Remicade | 18 |
The duration of hospital stays for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Days (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=657,418 ,0) | Visit 2 (n=304,126, 33) | Visit 3 (n=216, 58, 35) | Visit 4 (n=151, 60, 24) | Visit 5 (n=105, 35, 34) | Visit 6 (n=107, 49, 19) | Visit 7 (n=109, 45, 25) | Visit 8 (n=98, 29, 23) | Visit 9 (n=80, 38, 17) | Visit 10 (n=85, 29, 27) | Visit 11 (n=63, 19, 18) | |
| Remicade | 12.2 | 14.4 | 14.2 | 12.6 | 11.7 | 10.8 | 10.6 | 9.5 | 12.4 | 10.1 | 11.4 |
| Standard Therapy | 10.8 | 12.0 | 9.4 | 8.5 | 9.8 | 13.7 | 10.2 | 16.3 | 6.9 | 8.0 | 8.7 |
| Switched to Remicade | NA | 13.0 | 13.5 | 9.1 | 7.1 | 18.3 | 10.0 | 14.7 | 10.7 | 9.0 | 18.1 |
The number of participant hospital stays for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Hospital Stays (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1539, 1121, 0) | Visit 2 (n=1418, 920, 100) | Visit 3 (n=1334, 827, 152) | Visit 4 (n=1285, 779, 168) | Visit 5 (n=1221, 714, 188) | Visit 6 (n=1170, 665, 208) | Visit 7 (n=1111, 615, 219) | Visit 8 (n=1099, 589, 233) | Visit 9 (n=1046, 562, 229) | Visit 10 (n=1031, 535, 235) | Visit 11 (n=1006, 541, 248) | |
| Remicade | 0.7 | 0.3 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Standard Therapy | 0.5 | 0.2 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Switched to Remicade | NA | 0.5 | 0.4 | 0.2 | 0.3 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 |
The number of participants undergoing surgical procedures for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Surgical Procedures (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Basline; n=660, 419, 0) | Visit 2 (n=304, 126, 33) | Visit 3 (n=217, 57, 36) | Visit 4 (n=153, 60, 24) | Visit 5 (n=106, 36, 34) | Visit 6 (n=108, 49, 19) | Visit 7 (n=109, 45, 25) | Visit 8 (n=98, 29, 23) | Visit 9 (n=82, 38, 17) | Visit 10 (n=85, 29, 27) | Visit 11 (n=63, 19, 18) | |
| Remicade | 171 | 135 | 121 | 68 | 50 | 49 | 48 | 43 | 38 | 38 | 34 |
| Standard Therapy | 81 | 51 | 23 | 16 | 14 | 21 | 20 | 12 | 13 | 13 | 6 |
| Switched to Remicade | NA | 7 | 12 | 8 | 14 | 11 | 6 | 7 | 8 | 8 | 8 |
The number of participants with a draining fistula was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1541, 1120, 0) | Visit 2 (n=1420, 920, 100) | Visit 3 (n=1334, 827, 152) | Visit 4 (n=1285, 779, 168) | Visit 5 (n=1221, 714, 188) | Visit 6 (n=1169, 666, 208) | Visit 7 (n=1110, 615, 219) | Visit 8 (n=1097, 588, 233) | Visit 9 (n=1046, 562, 229) | Visit 10 (n=1030, 535, 235) | Visit 11 (n=1006, 541, 248) | |
| Remicade | 349 | 211 | 170 | 146 | 125 | 114 | 97 | 105 | 98 | 85 | 87 |
| Standard Therapy | 96 | 51 | 41 | 31 | 29 | 26 | 31 | 23 | 32 | 15 | 16 |
| Switched to Remicade | NA | 16 | 19 | 12 | 15 | 15 | 15 | 16 | 15 | 20 | 20 |
The participant assessment of overall health status was evaluated at baseline and each study visit. The overall health status questionnaire asked participants to rate their current health status over the prior 24 hours as 1=best possible, 2=much better than average, 3=better than average, 4=average, 5=worse than average, 6=much worse than average, or 7=worst possible. Scores ranged from 1 to 7 with lower scores indicating better health status. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Score on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1526, 1116, 0) | Visit 2 (n=1344, 903, 95) | Visit 3 (n=1280, 809, 146) | Visit 4 (n=1217, 755, 162) | Visit 5 (n=1160, 704, 184) | Visit 6 (n=1110, 649, 202) | Visit 7 (n=1046, 606, 212) | Visit 8 (n=1044, 573, 221) | Visit 9 (n=999, 544, 223) | Visit 10 (n=963, 520, 227) | Visit 11 (n=956, 527, 235) | |
| Remicade | 4.3 | 3.3 | 3.2 | 3.2 | 3.1 | 3.1 | 3.1 | 3.1 | 3.1 | 3.0 | 3.0 |
| Standard Therapy | 3.9 | 3.3 | 3.1 | 3.0 | 3.1 | 3.0 | 3.0 | 3.0 | 2.9 | 2.8 | 2.8 |
| Switched to Remicade | NA | 3.9 | 3.6 | 3.5 | 3.2 | 3.4 | 3.3 | 3.2 | 3.2 | 3.1 | 3.1 |
The Harvey-Bradshaw Index of Crohn's Disease Acitivity was evaluated at each study visit. The Harvey-Bradshaw Index evaluates participants' general health in the day prior in the domains of well being, abdominal pain, number of liquid stools per day, and abdominal mass and complications and was evaluated on the day of the study visit. The score is derived from a 0-4 score for general well being, 0-3 for abdmonial pain, raw score for number of liquid stools per day, 0-3 for abdominal mass, and raw score for complications. The total score is from 0 to infinity, with lower scores indicating better outcomes. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Score on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1505, 1106, 0) | Visit 2 (n=1320, 876, 91) | Visit 3 (n=1250, 785, 143) | Visit 4 (n=1196, 742, 159) | Visit 5 (n=1127, 692, 181) | Visit 6 (n=1070, 647, 199) | Visit 7 (n=1023, 592, 209) | Visit 8 (n=1015, 562, 224) | Visit 9 (n=953, 546, 219) | Visit 10 (n=936, 526, 225) | Visit 11 (n=918, 525, 238) | |
| Remicade | 8.2 | 4.1 | 3.7 | 3.8 | 3.7 | 3.6 | 3.6 | 3.6 | 3.6 | 3.4 | 3.4 |
| Standard Therapy | 6.2 | 3.8 | 3.5 | 3.2 | 3.4 | 3.1 | 3.0 | 3.2 | 2.9 | 2.7 | 2.7 |
| Switched to Remicade | NA | 6.0 | 4.4 | 4.8 | 4.9 | 4.5 | 4.1 | 4.1 | 4.4 | 4.3 | 4.2 |
The participant work/daily activity status score was evaluated at each study visit. The work/daily activity questionnaire asked participants to rate their level of daily functioning on a scale of 1 to 10 with a lower score indicating less of an impact of Crohn's disease on work or daily life functioning. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Score on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1496, 1108, 0) | Visit 2 (n=1316, 895, 94) | Visit 3 (n=1235, 797, 143) | Visit 4 (n=1192, 738, 159) | Visit 5 (n=1128, 694, 179) | Visit 6 (n=1077, 638, 201) | Visit 7 (n=1030, 601, 207) | Visit 8 (n=1025, 571, 221) | Visit 9 (n=982, 542, 222) | Visit 10 (n=934, 514, 225) | Visit 11 (n=925, 521, 235) | |
| Remicade | 5.9 | 4.2 | 3.8 | 3.6 | 3.4 | 3.3 | 3.2 | 3.3 | 3.3 | 3.1 | 3.2 |
| Standard Therapy | 4.9 | 3.7 | 3.2 | 2.9 | 3.0 | 2.7 | 2.8 | 2.7 | 2.6 | 2.4 | 2.4 |
| Switched to Remicade | NA | 5.5 | 4.8 | 4.3 | 4.0 | 3.9 | 3.6 | 3.5 | 3.5 | 3.6 | 3.6 |
1 review available for azathioprine and Hematologic Diseases
| Article | Year |
|---|---|
[Blood hypereosinophilias. IV. Symptomatic hypereosinophilias: connective tissue diseases, neoplasms, blood diseases, various causes].
Topics: Aged; Asthma; Azathioprine; Connective Tissue Diseases; Cortisone; Eosinophilia; Female; Hematologic | 1985 |
2 trials available for azathioprine and Hematologic Diseases
| Article | Year |
|---|---|
Association between inosine triphosphate pyrophosphohydrolase deficiency and azathioprine-related adverse drug reactions in the Chinese kidney transplant recipients.
Topics: Aged; Asian People; Azathioprine; Drug-Related Side Effects and Adverse Reactions; Female; Gastroint | 2010 |
Side effects of mycophenolate mofetil versus azathioprine in iranian renal transplant recipients (single-center experience).
Topics: Adult; Azathioprine; Gastrointestinal Diseases; Graft Rejection; Hematologic Diseases; Humans; Immun | 2002 |
19 other studies available for azathioprine and Hematologic Diseases
| Article | Year |
|---|---|
Clinical and histologic features of Azathioprine-induced hepatotoxicity.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Azathioprine; Bilirubin; Chemical and Drug Induce | 2017 |
Long-term Safety and Efficacy of Low-dose Azathioprine and Allopurinol Cotherapy in Inflammatory Bowel Disease: A Large Observational Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites; Azathioprine; Blood Sedime | 2016 |
Bronchus-associated Lymphoid Tissue in Kabuki Syndrome with Associated Hyper-IgM Syndrome/Common Variable Immunodeficiency.
Topics: Abnormalities, Multiple; Adult; Antineoplastic Agents, Immunological; Azathioprine; Biopsy; Bronchi; | 2016 |
Frequency of thiopurine methyltransferase mutation in patients of Mediterranean area with inflammatory bowel disease and autoimmune disorders.
Topics: Adult; Autoimmune Diseases; Azathioprine; Female; Hematologic Diseases; Heterozygote; Homozygote; Hu | 2016 |
Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azathio | 2017 |
Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients.
Topics: Adult; Aged; Asian People; Azathioprine; Chemical and Drug Induced Liver Injury; Dose-Response Relat | 2009 |
Impact of the heterozygous TPMT*1/*3C genotype on azathioprine-induced myelosuppression in kidney transplant recipients in Thailand.
Topics: Adolescent; Adult; Aged; Alleles; Asian People; Azathioprine; Female; Gene Frequency; Genotype; Hema | 2009 |
Thiopurine methyltransferase screening before azathioprine prescription: a physician survey.
Topics: Antirheumatic Agents; Attitude of Health Personnel; Azathioprine; Dose-Response Relationship, Drug; | 2013 |
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine.
Topics: Adult; Antirheumatic Agents; Azathioprine; Female; Hematologic Diseases; Heterozygote; Humans; Male; | 1998 |
[Bone marrow depression after azathioprine. New discoveries on an old drug].
Topics: Aged; Antimetabolites, Antineoplastic; Azathioprine; Bone Marrow Cells; Female; Genotype; Hematologi | 2000 |
Cadaveric renal graft acceptance without azathioprine.
Topics: Azathioprine; Cadaver; Creatinine; Female; Graft Rejection; Graft Survival; Hematologic Diseases; He | 1979 |
[Long-term use of immunosuppressants in patients with kidney transplants].
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Chemical and Drug Induced Liver Injury; Female; Gastro | 1975 |
Allopurinol-azathioprine interaction.
Topics: Aged; Allopurinol; Azathioprine; Drug Interactions; Hematologic Diseases; Humans; Male; Middle Aged | 1991 |
Azathioprine toxicity in neuromuscular disease.
Topics: Allopurinol; Azathioprine; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Leukopen | 1986 |
[Immunosuppressive agents in hematology].
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Agranulocytosis; Anemia, Hemolytic, Autoimmune | 1970 |
Wegener's granulomatosis.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Child, Preschool; Cyclophosphamide; Diagnosis, Differe | 1974 |
Azathioprine.
Topics: Arthritis, Rheumatoid; Asthma; Autoimmune Diseases; Azathioprine; Colitis, Ulcerative; Glomeruloneph | 1973 |
[Follow-up studies of Zurich clinical cases].
Topics: Adult; Azathioprine; Cadaver; Chronic Disease; Follow-Up Studies; Glomerulonephritis; Hematologic Di | 1967 |
[Immunosuppressive effect of cytostatics in the clinic].
Topics: Azathioprine; Colitis, Ulcerative; Collagen Diseases; Granulomatosis with Polyangiitis; Hematologic | 1970 |